Nervous System News and Research

Latest Nervous System News and Research

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Cephalon to acquire Swiss-based pharmaceutical company

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company.

1 Feb 2010

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.

1 Feb 2010

Tips to prevent potential health problems in the future

A new year, a new YOU! Some of the most popular resolutions include getting healthier. The Minnesota Chiropractic Association (MCA) encourages better health through lifestyle choices.

30 Jan 2010

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

A new study from UC Davis Health System identifies for the first time a brain protein called SynDIG1 that plays a critical role in creating and sustaining synapses, the complex chemical signaling system responsible for communication between neurons.

30 Jan 2010

Should medical workers participate in the development of "medicalized" weapons?

(Garrison, NY) The latest issue of the Hastings Center Report features articles on "medicalized" weapons that temporarily incapacitate targets, sharing the benefits of newly found biological resources, and applications of GINA (the Genetic Information Nondisclosure Act).

29 Jan 2010

NIDA supports Omeros' Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers.

28 Jan 2010

Centering Healthcare Institute receives the Cares Award for its CenteringPregnancy Group Prenatal Care program

Centering Healthcare Institute has been honored by the Premier healthcare alliance with the 18th Annual Monroe E. Trout Premier Cares Award for its CenteringPregnancy Group Prenatal Care program, which provides an innovative prenatal group care model now present in more than 300 sites across America. Centering Healthcare Institute last night received the Cares Award and $70,000 for the work it has done to provide care to mothers and babies nationwide.

28 Jan 2010

Researchers to test newest implant in restoring vision damaged by disease

Researchers trying to restore vision damaged by disease have found promise in a tiny implant that sows seeds of new cells in the eye.

28 Jan 2010

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

The ALS Therapy Development Institute and Oxford BioMedica announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

28 Jan 2010

Children with cancer are treated with proton therapy at ProCure Proton Therapy Center

Children with cancer are now being accepted for treatment at the ProCure Proton Therapy Center in Oklahoma, where a wide range of tumors are treated with proton therapy, an alternative to X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

28 Jan 2010

Sepracor's STEDESA NDA: FDA extends PDUFA action date

Sepracor Inc. today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency now anticipates completing its review of the STEDESA™ (eslicarbazepine acetate) New Drug Application (NDA) on April 30, 2010, which is a three-month extension to the original Prescription Drug User Fee Act (PDUFA) date of January 30, 2010.

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix’s Parkinson’s disease program. The new allowances to U.S. Patent Number 765,446, entitled “Glutamic acid decarboxylase (GAD) based delivery systems,” broaden the patent’s coverage beyond Parkinson’s disease to include the use of GAD65 in the treatment of other neurological and related disorders.

27 Jan 2010

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

EpiCept Corporation announced today that EpiCeptTM NP-1 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of post-herpetic neuralgia (PHN). NP-1 is a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies.

27 Jan 2010

AAN guideline finds diazepam drug is effective for treating children with cerebral palsy

A new guideline from the American Academy of Neurology and the Child Neurology Society finds botulinum toxin type A to be an effective treatment for spasticity, muscle tightness that interferes with movement, in children and adolescents with cerebral palsy, but poses some risk.

27 Jan 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

Heart research news and updates from University of Houston

Matters of the heart dominate in February with Valentine's Day and the American Heart Association's 'Heart Month' topping the list. As you consider story ideas ranging from heart disease to relationships, keep in mind these resources from the University of Houston.

23 Jan 2010

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

23 Jan 2010

Nervous System News and Research

Latest Nervous System News and Research

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Cephalon to acquire Swiss-based pharmaceutical company

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Tips to prevent potential health problems in the future

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

Should medical workers participate in the development of "medicalized" weapons?

NIDA supports Omeros' Addiction program

Centering Healthcare Institute receives the Cares Award for its CenteringPregnancy Group Prenatal Care program

Researchers to test newest implant in restoring vision damaged by disease

ALS TDI and Oxford BioMedica extend collaboration to develop gene therapies for Lou Gehrig's disease

Children with cancer are treated with proton therapy at ProCure Proton Therapy Center

Sepracor's STEDESA NDA: FDA extends PDUFA action date

Abbott declares quarterly dividend of 40 cents per share

US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

Geron collaborates to explore hESC-based product for Alzheimer’s disease

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

AAN guideline finds diazepam drug is effective for treating children with cerebral palsy

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Heart research news and updates from University of Houston

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Nervous System News and Research

Latest Nervous System News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in